Investors seek durability gains for Immatics’ TCR therapy

An abstract released ahead of the SITC conference unveils impressive solid tumor response rates for IMA203 from Immatics, but deepens concerns about durability of the TCR cell therapy modality.

Immatics N.V. (NASDAQ:IMTX) reported that the PRAME-targeting engineered TCR cell therapy led to eight partial responses for an ORR of 50% in 16 evaluable solid tumor patients who had received a median of four prior therapies, across three dose cohorts. Disease control rate was 94% (15/16)...